Hemophilia

Hemophilia


​FOR EACH DISEASE, TRIO DEVELOPS A CUSTOM SOLUTION THAT CAPTURES PATIENT LEVEL DATA THROUGHOUT THE PATIENT JOURNEY, ALL IN REAL-TIME. TRIO’S COVERAGE INCLUDES APPROVED DRUG REGIMENS, PHYSICIANS AND PHARMACIES WITHOUT BIAS.

Data Elements


DEMOGRAPHICS

  • Diagnosis
  • Age
  • Gender
  • Race / Ethnicity
  • BMI
  • Height / Weight

PT CHARACTERISTICS

  • Hemophilia Severity
  • IV Access Method
  • Target Joints
  • Prophylaxis vs. Breakthrough Bleeding Products
  • Inhibitor Use
  • Last Bleed Date
  • Number of Bleeds

PRIOR HISTORY

  • First Diagnosis of Hemophilia Date
  • Prior Regimen
  • Prior Treatment Status (new to therapy or refill)
  • Duration of Therapy
  • Reason for Switch

PT ADHERENCE

  • Current Therapy
  • Duration
  • Dose
  • Prophylaxis Product Use
  • Bleeding Product Use
  • % Doses Taken
  • % Doses Missed

PROVIDERS

  • Type (Physician, NP, PA)
  • Specialty
  • Academic vs Community
  • Specialty Pharmacy vs. Hemophilia Treatment Center

PAYERS

  • Type (Commercial, Medicare, Medicaid, Dual Eligible)
  • Payer Name
  • Self-Pay and Patient Assistance
  • Eligibility
  • Correct PA form
  • Denial Reason

PA TIMELINE

  • Copay Amount
  • PA Submitted Date
  • Approval / Denial Date
  • Appeals Submitted

DISPENSING INFO

  • Current Treatment Regimen Rx
  • Intended Regimen
  • Actual Regimen
  • Duration
  • Dispensed Regimen
  • Duration / Refills
  • Gaps in Therapy

Patient Tear Sheet


Real Time Aggregated Data is organized and visualized at a patient level for immediate and longitudinal insight.
Click on image below for a 3 page PDF of a Patient Tear Sheet.

Publications


2022


Effects of Pharmacokinetic Assessment on Clinical Outcomes for Patients with Moderate to Severe Hemophilia A

Guy Young, Michael Callaghan, Vinod Balasa, Amit Soni, Sanjay Ahuja, Jonathan C. Roberts, Mindy L. Simpson, Andrew Frick, Ali G. Mokdad, Shan Xing, and Jorge Caicedo

Poster Presented at: American Thrombosis & Hemostasis Network (ATHN)

Conference dates: October 19, 2022 - October 21, 2022


Real-World Study of Rurioctocog Alfa Pegol and Emicizumab in US Clinical Practice Among Patients with Hemophilia A

Shawn X. Sun, Andrew Frick, Vinod Balasa, and Jonathan C. Roberts

DOI: 10.1080/17474086.2022.2112171

Manuscript Published in: EXPERT REVIEW OF HEMATOLOGY

Date of Publication: August 24, 2022


Effects of Pharmacokinetic Assessment on Clinical Outcomes for Patients with Moderate to Severe Hemophilia A

Guy Young, Michael Callaghan, Vinod Balasa, Amit Soni, Sanjay Ahuja, Jonathan C. Roberts, Mindy L. Simpson, Andrew Frick, Ali G. Mokdad, Shan Xing, and Jorge Caicedo

International Society on Thrombosis and Haemostasis 2022; 2022 July 9-13: Abstract PB0688

Poster Presented at: International Society on Thrombosis and Haemostasis (ISTH)

Conference dates: July 9, 2022 - July 13, 2022


Effects of Pharmacokinetic Assessment on FVIII Consumption and Estimated Costs for Patients with Moderate to Severe Hemophilia A

Guy Young, Michael Callaghan, Vinod Balasa, Amit Soni, Sanjay Ahuja, Jonathan C. Roberts, Mindy L. Simpson, Andrew Frick, Ali G. Mokdad, Shan Xing, and Jorge Caicedo

International Society on Thrombosis and Haemostasis 2022; 2022 July 9-13: Abstract PB0689

Poster Presented at: International Society on Thrombosis and Haemostasis (ISTH)

Conference dates: July 9, 2022 - July 13, 2022




2021


A Retrospective Observational Descriptive Study on the Effectiveness and Usage of Emicizumab and Antihemophilic Factor (recombinant), Fc Fusion Protein in Patients with Hemophilia A in the US

Alex Cockerham, Amanda Wilson, Andrew Frick, and Pronabesh DasMahapatra

DOI: 10.1182/blood-2021-148325

Poster Presented at: American Society of Hematology (ASH)

Conference dates: December 11, 2021 - December 14, 2021


A Retrospective Study of Rurioctocog Alfa Pegol and Emicizumab Wastage, Consumption, and Costs in US Clinical Practice Among Patients with Hemophilia A

Shawn X. Sun, Andrew Frick

10.18553/jmcp.2021.27.4-a.s1

Poster Presented at: Academy of Managed Care Pharmacy (AMCP)

Conference dates: April 12, 2021 - April 16, 2021


A Retrospective Study of the Impact of Switching Patients with Haemophilia A to Rurioctocog Alfa Pegol or Emicizumab in US Practice

Shawn X. Sun, Andrew Frick

DOI: 10.1111/hae.14236: ABS039

Poster Presented at: European Association for Haemophilia and Allied Disorders

Conference dates: February 3, 2021 - February 5, 2021




2020


Real-World Outcomes Before and After Switching From Standard Half-Life Factor VIII to Rurioctocog Alfa Pegol in The United States

Shawn X. Sun, Scott Milligan

Res Pract Thromb Haemost. 2020; 4 (Suppl 1)

Poster Presented at: International Society on Thrombosis and Haemostasis (ISTH)

Conference dates: July 12, 2020 - July 14, 2020


A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States

Louis Aledort, MD; Scott Milligan, PhD; Maureen Watt, MSc; and Jason Booth, MPH

DOI: 10.18553/jmcp.2020.26.4.492

Manuscript Published in: Journal of Managed Care & Specialty Pharmacy

Date of Publication: April 1, 2020




2019


Real-world, Age-Stratified FVIII Consumption and Bleed Outcomes Before and After Switching to Rurioctocog Alfa Pegol in a Retrospective, Observational Study Using US Specialty Pharmacy Data

Maureen Watt and Scott Milligan

DOI: 10.1182/blood-2019-124101

Poster Presented at: The American Society of Hematology (ASH)

Conference dates: December 7, 2019 - December 10, 2019


A Retrospective, Observational Study Using Specialty Pharmacy Data of Rurioctocog Alfa Pegol Use in the United States

Maureen Watt and Scott Milligan

DOI: 10.1002/rth2.12229

Poster Presented at: International Society on Thrombosis and Haemostasis (ISTH)

Conference dates: July 6, 2019 - July 10, 2019




2018


A Retrospective, Observational Study of BAX 855 in Clinical Practice in the United States

J. Booth, M. Watt, S. Milligan, and L. Aledort

DOI: 10.18553/jmcp.2018.24.4-a.s1

Poster Presented at: Academy of Managed Care Pharmacy (AMCP)

Conference dates: April 23, 2018 - April 26, 2018